Literature DB >> 28915103

MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.

Jurgen Henk Runge1, Loek Pieter Smits1, Joanne Verheij1, Annekatrien Depla1, Sjoerd Douwe Kuiken1, Bert Cornelis Baak1, Aart Johannes Nederveen1, Ulrich Beuers1, Jaap Stoker1.   

Abstract

Purpose To prospectively compare the diagnostic accuracy of controlled attenuation parameter (CAP) obtained with transient elastography and proton density fat fraction (PDFF) obtained with proton magnetic resonance (MR) spectroscopy with results of liver biopsy in a cohort of adult patients suspected of having nonalcoholic fatty liver disease (NAFLD). Materials and Methods The institutional review board approved this study. Informed consent was obtained from all patients. The authors evaluated 55 patients suspected of having NAFLD (40 men, 15 women). Patients had a median age of 52.3 years (interquartile range [IQR], 43.7-57.6 years) and a median body mass index of 27.8 kg/m2 (IQR, 26.0-33.1 kg/m2). CAP and PDFF measurements were obtained on the same day, within 27 days of biopsy (IQR, 7-44 days). CAP and PDFF were compared between steatosis grades by using the Jonckheere-Terpstra test. Diagnostic accuracies of CAP and PDFF for grading steatosis were assessed with receiver operating characteristic (ROC) analysis. Within-weeks reproducibility (CAP and PDFF) and within-session repeatability were assessed with linear regression analyses, intraclass correlation coefficients, and coefficients of variation. Results Steatosis grades at liver biopsy were distributed as follows: S0, five patients; S1, 24 patients; S2, 17 patients; and S3, nine patients. Both PDFF and CAP helped detect histologically proven steatosis (≥S1), but PDFF showed better diagnostic accuracy than CAP in terms of the area under the ROC curve (0.99 vs 0.77, respectively; P = .0334). PDFF, but not CAP, enabled the grading of steatosis (P < .0001). For within-weeks reproducibility, the intraclass correlation coefficient with PDFF was higher than that with CAP (0.95 vs 0.65, respectively; P = .0015); coefficients of variation were similar (19% vs 11%, P = .55). Within-session repeatability of CAP was good, with a coefficient of variation of 4.5%. Conclusion MR spectroscopy-derived PDFF is superior to CAP in detecting and grading liver steatosis in human NAFLD. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2017        PMID: 28915103     DOI: 10.1148/radiol.2017162931

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

Review 1.  European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.

Authors:  Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda
Journal:  United European Gastroenterol J       Date:  2022-08-12       Impact factor: 6.866

2.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

Review 3.  Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease.

Authors:  Jérémy Dana; Aïna Venkatasamy; Antonio Saviano; Joachim Lupberger; Yujin Hoshida; Valérie Vilgrain; Pierre Nahon; Caroline Reinhold; Benoit Gallix; Thomas F Baumert
Journal:  Hepatol Int       Date:  2022-02-09       Impact factor: 9.029

4.  Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly.

Authors:  Tao Xie; Hailin Ding; Mingfeng Xia; Xiaobiao Zhang; Wei Sun; Tengfei Liu; Ye Gu; Chongjing Sun; Fan Hu
Journal:  Endocrine       Date:  2018-09-10       Impact factor: 3.633

5.  Unenhanced computed tomography for non-invasive diagnosis of hepatic steatosis with low tube potential protocol.

Authors:  Dong Kyun Kim; Joon-Il Choi; Yunjung Choi; Seo Yeon Youn; Hokun Kim
Journal:  Quant Imaging Med Surg       Date:  2022-02

6.  Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.

Authors:  Marian A Troelstra; Julia J Witjes; Anne-Marieke van Dijk; Anne L Mak; Oliver Gurney-Champion; Jurgen H Runge; Diona Zwirs; Daniela Stols-Gonçalves; Aelko H Zwinderman; Marije Ten Wolde; Houshang Monajemi; Sandjai Ramsoekh; Ralph Sinkus; Otto M van Delden; Ulrich H Beuers; Joanne Verheij; Max Nieuwdorp; Aart J Nederveen; Adriaan G Holleboom
Journal:  J Magn Reson Imaging       Date:  2021-05-15       Impact factor: 5.119

7.  Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta.

Authors:  Carolina Chaves; Eveline Bruinstroop; Samuel Refetoff; Paul M Yen; João Anselmo
Journal:  Thyroid       Date:  2021-02-19       Impact factor: 6.506

Review 8.  Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Authors:  Hannah K Drescher; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

Review 9.  Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications.

Authors:  Duanghathai Pasanta; Khin Thandar Htun; Jie Pan; Montree Tungjai; Siriprapa Kaewjaeng; Hongjoo Kim; Jakrapong Kaewkhao; Suchart Kothan
Journal:  Diagnostics (Basel)       Date:  2021-05-07

10.  Dicomflex: A novel framework for efficient deployment of image analysis tools in radiological research.

Authors:  Roland Stange; Nicolas Linder; Alexander Schaudinn; Thomas Kahn; Harald Busse
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.